Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05115435
Other study ID # RDNLP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date November 1, 2021

Study information

Verified date November 2021
Source Inonu University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study was conducted experimentally to evaluate the effect of neurolinguistic programming on COVID-19 fear in kidney transplant patients.


Description:

The study was conducted experimentally (prospective randomized single-blind clinical trial model) to evaluate the effect of neurolinguistic programming (NLP) on fear of Covid-19 in kidney transplant patients. The study was carried out between June 2021 and October 2021. Personal Information Form and Fear of COVID-19 Scale (FCV-19S) were used to collect data. The data obtained from the research were evaluated with SPSS 25. According to the calculation made using G*power 3.1 software, the sample size was determined as 74 (each group 37) with an effect size of 0.80, a margin of error of 0co.05, a confidence level of 0.95, and a population representation of 0.95. Simple random sampling method, one of the probability sampling methods, was used to determine the participants. Single-group columns between 1 and 300 were created using the Random Integer Generator method, which located in the Numbers sub-heading of the random.org website for the participants who met the sample selection criteria. Participants were randomly assigned to numbers 1 and 2, considering the numbers 1 and 2 in the column. The number of the experimental or control group was determined by drawing lots at the beginning of the research


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date November 1, 2021
Est. primary completion date August 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:Patients who could communicate verbally, had no hearing problems, had a high or moderate fear of Covid-19 (20 or more), and had not applied NLP before were included in the study. - Exclusion Criteria: Patients who wanted to leave voluntarily at any stage after being included in the study, and who had to be hospitalized again for organ rejection or any other reason while the study was ongoing, were excluded from the study. -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
neuro linguistic programming
Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change

Locations

Country Name City State
Turkey Inönü Üniversitesi Malatya
Turkey Inönü University Malatya

Sponsors (1)

Lead Sponsor Collaborator
Inonu University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary A mean total score on the Fear of COVID-19 Scale (FCV-19S) Fear of COVID-19 Scale . After applying the personal information form and Fear of COVID-19 Scale (FCV-19S) to the patients in the experimental group, the sub-modality technique of NLP was applied once, and then FCV-19S was applied again one week later
See also
  Status Clinical Trial Phase
Completed NCT01680952 - Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients Phase 4
Completed NCT06044558 - Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics
Recruiting NCT05039788 - Observational Single-center Study of the Relationship Between Arterial Hypertension and Hypervolemia Defined by Self-measurement of Impedancemetry in Kidney Transplant Patients With Transplantation Less Than 6 Months Old
Completed NCT03356522 - Study of Trabecular Bone Score (TBS) as a Fracture Risk Factor in Chronic Renal Failure N/A